Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
Key takeways: Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for pathology AI lies in personalized medicine with big data. Better characterization of the patient...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue typesNEW YORK, NY and BROOMFIELD, CO — February 17, 2022 — Paige, the global leader in AI-based diagnostic software in pathology, and Flagship...
EVENTS
Visit Flagship at the Spatial Biology for Drug Development Summit. October 11-13, 2023. Join us at the inaugural Spatial Biology for Drug Development Summit to explore implementation strategies, challenges in interpretation, and how this rapidly changing technology is...
Visit us at booth E30 to learn how we can partner for end-to-end support of your research and development program. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 13th Annual World Clinical Biomarkers & CDx...
Flagship Bioscience is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance your precision medicine strategy. Attending the 2023...